Newron Pharmaceuticals S.p.A. & EA Pharma Ltd
Milan, Italy · Biopharma, Biotechnology, Health Care
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. focused on pharmaceutical development.
Key facts
- Headquarters
- Milan, Italy
- Employees
- 23
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- http://www.newron.com/
- Company page
Recent activity at Newron Pharmaceuticals S.p.A. & EA Pharma Ltd
- : Newron Pharmaceuticals secures EUR 5.5 million through an investor group as part of up to EUR 38 million financing to support the ENIGMA-TRS Phase 3 program.
- : Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Territories
- : Newron Receives Fifth Tranche From Financing Agreement With European Investment Bank (Eib)
- : Newron Receives Fourth Tranche From Financing Agreement With European Investment Bank (Eib)
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Venture | $5.5M |
| Oct 2021 | Debt Financing | Undisclosed |
| Sep 2021 | Debt Financing | Undisclosed |
Leadership
- Filippo, Vice President Operations
- Laura, Vice President Business Development
- Roberto, Chief Financial Officer, IAB Member
Verified email and direct lines for Newron Pharmaceuticals S.p.A. & EA Pharma Ltd’s decision-makers are on Fundz. See plans
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd in the news
- Working capital per share of Newron Pharmaceuticals S.p.A. – HAN:NP5 - TradingView (Sep 30, 2026)
- ETFs Investing in Newron Pharmaceuticals S.p.A. Stocks - TradingView (Sep 30, 2026)
- These Analysts Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Sales Are Under Threat - simplywall.st (Oct 02, 2026)
- Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study - GlobeNewswire (Sep 25, 2026)
- US FDA Maintains Clinical Hold on Patient Enrollment for Newron's Phase 3 Trial of Schizophrenia Drug - marketscreener.com (Sep 28, 2026)
- Newron presents H1 2026 results and provides corporate update - Yahoo Finance UK (Sep 22, 2026)
- Newron's Cash Runway Meets Its Clinical Clock as Evenamide Pivots Away From the US - AD HOC NEWS (Oct 03, 2026)
- Newron Pharmaceuticals S.P.A. Provides Update on Phase 3 Enigma-Trs 2 Study with Evenamide - marketscreener.com (Sep 25, 2026)
Companies similar to Newron Pharmaceuticals S.p.A. & EA Pharma Ltd
- OnCusp Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Dimerix Limited · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Cantargia AB · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- BerGenBio ASA · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- LAVA Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Newron Pharmaceuticals S.p.A. & EA Pharma Ltd: questions and answers
What does Newron Pharmaceuticals S.p.A. & EA Pharma Ltd do?
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. EA Pharma Co., Ltd. is a subsidiary of Eisai Co., Ltd. focused on pharmaceutical development.
Where is Newron Pharmaceuticals S.p.A. & EA Pharma Ltd headquartered?
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd is headquartered in Milan, Italy.
How many employees does Newron Pharmaceuticals S.p.A. & EA Pharma Ltd have?
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd has about 23 employees.
Has Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised funding?
Yes. Fundz has recorded 3 funding events for Newron Pharmaceuticals S.p.A. & EA Pharma Ltd. The most recent, $5.5M, was in Sep 2026.
Who leads Newron Pharmaceuticals S.p.A. & EA Pharma Ltd?
Filippo is a Vice President Operations at Newron Pharmaceuticals S.p.A. & EA Pharma Ltd.
What is the latest news on Newron Pharmaceuticals S.p.A. & EA Pharma Ltd?
On Sep 08, 2026, Newron Pharmaceuticals secures EUR 5.5 million through an investor group as part of up to EUR 38 million financing to support the ENIGMA-TRS Phase 3 program.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy